If you have been reading about BPC-157 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Rusfertide, sold under the brand name Mimrylo, is a medication used for the treatment of polycythemia vera. It is a hepcidin mimetic. It was developed by Protagonist Therapeutics in partnership with Takeda Pharmaceuticals. It is given by subcutaneous injection. The most common adverse reactions include injection site reactions and anemia. Rusfertide was approved for medical use in the United States in August 2026. It is the first approved treatment for polycythemia vera that mimics hepcidin, a hormone that naturally regulates iron in the body.
Athletes competing in power sports, bodybuilding, professional wrestling, mixed martial arts, swimming, baseball, strength sports, track and field, cycling, soccer, weight lifting, skiing and endurance sports have been said to abuse human growth hormone, including in combination with other performance-enhancing drugs such as androgenic anabolic steroids including testosterone, certain products which claim to enhance HGH, and erythropoietin (among others). There has never been an adequately large randomized controlled trial showing definitively that HGH provides benefits to athletes and that there are no significant adverse drug reactions; there have been many small studies and several of these studies were recently reviewed and analyzed in a meta-analysis. While the authors indicated that the meta-analysis was limited by the fact that few of the included studies evaluated athletic performance and by the fact that dosing protocols in the studies may not reflect real-world doses and regimens, their conclusions were as follows:
== Further reading == Facts on World Scouting, Boy Scouts International Bureau, Ottawa, Canada, 1961 Laszlo Nagy, 250 Million Scouts, The World Scout Foundation and Dartnell Publishers, 1985 Eduard Vallory, "World Scouting: Educating for Global Citizenship", Palgrave Macmillan, New York, 2012
Sources: en.wikipedia.org
==== Valvular heart disease ==== Diseased heart valves that have become abnormally narrow or abnormally leaky may require surgery. This is traditionally performed as an open surgical procedure to replace the damaged heart valve with a tissue or metallic prosthetic valve. In some circumstances, the tricuspid or mitral valves can be repaired surgically, avoiding the need for a valve replacement. Heart valves can also be treated percutaneously, using techniques that share many similarities with percutaneous coronary intervention. Transcatheter aortic valve replacement is increasingly used for patients considered to be at very high risk for open valve replacement.
Proteolytic venom dismantles the molecular surroundings, including at the site of the bite. Hemotoxic venom acts on the cardiovascular system, including the heart and blood. Neurotoxic venom acts on the nervous system, including the brain. Cytotoxic venom has a localized action at the site of the bite. Myotoxic venom acts on the muscular system.
==== Food intake ==== Secretin and its receptor are found in discrete nuclei of the hypothalamus, including the paraventricular nucleus and the arcuate nucleus, which are the primary brain sites for regulating body energy homeostasis. It was found that both central and peripheral injection of Sct reduce food intake in mouse, indicating an anorectic role of the peptide. This function of the peptide is mediated by the central melanocortin system.
== Sexual deviance == The antigonadotropic antiandrogens CPA, medroxyprogesterone acetate (MPA), and GnRH analogues have all been widely used to treat paraphilias (e.g., pedophilia) and hypersexuality in men. They suppress androgen levels to castrate or near-castrate levels and are highly effective in reducing sexual urges, arousal, and behaviors. In addition, they are used to treat sex offenders as a means of chemical castration for the purpose of reducing the likelihood of recidivism. Although they have not been studied in the treatment of paraphilias and hypersexuality, NSAAs like flutamide and bicalutamide have been suggested as potential medications for these indications and may have superior tolerability and safety relative to antigonadotropic antiandrogens. As an example, because NSAAs do not reduce estrogen levels, unlike antigonadotropic antiandrogens, they preserve bone mineral density (BMD) and have little or no risk of osteoporosis and associated bone fractures. However, due to unopposed estrogen signaling, a substantial incidence of gynecomastia is associated with NSAAs. In addition to potential monotherapy use, NSAAs have been advocated for temporarily suppressing sex drive during the start of GnRH agonist treatment via prevention of the increased androgen signaling associated with the initial testosterone flare. Though treatment of paraphilias and hypersexuality with selective AR antagonists is a seemingly sound strategy, this may not be true in practice.
Sources: en.wikipedia.org
== Overview of technique == Freeze branding can permanently alter the color of a mammal's coat, leaving the branded area white for the rest of its life. This is ultimately caused by the formation of ice crystals within melanocytes, the cells that normally coat the hair shaft with pigment as the growth root pushes the hair out of the follicle. This ice physically disrupts the microtubules along which melanin granules are transported from within the cell to its membrane, where they normally undergo exocytosis. That cellular machinery is permanently damaged after the cells thaw, preventing the surviving melanocytes from ever again secreting melanin. Most melanocytes rapidly fall into apoptosis and fail to regenerate. There are two types of freeze branding, one requiring a longer application of the brand than the other. Pigmented animals may be branded more quickly than pale animals because dark coats require only the hair follicles' pigmentation apparatus to be destroyed. This causes the branded skin to regrow hair to which no pigment has been applied as it leaves the hair sheath, rendering the shaft microscopically clear and macroscopically white. Pale animals require a longer branding time to kill the deepest part of the follicle, which secretes the hair shaft itself. This prevents any hair regrowth, leaving a bald patch of skin generally darker than the animal's coat. Freeze branding thereby ensures high contrast even on white-coated animals. The difference in branding time between the two methods is minimal, often separated by only a few seconds.
An insulinoma is a tumour of the pancreas that is derived from beta cells and secretes insulin. It is a rare form of a neuroendocrine tumour. Most insulinomas are benign in that they grow exclusively at their origin within the pancreas, but a minority metastasize. Insulinomas are one of the functional pancreatic neuroendocrine tumour (PNET) group ("functional" because it increases production of insulin). In the Medical Subject Headings classification, insulinoma is the only subtype of "islet cell adenoma". Beta cells secrete insulin in response to increases in blood glucose. The resulting increase in insulin acts to lower blood glucose back to normal levels, the point at which further secretion of insulin is stopped. In contrast, the secretion of insulin by insulinomas is rather independent of blood glucose; these tumours continue to secrete insulin, causing blood glucose levels to fall further below normal. As a result, patients present symptoms of low blood glucose (hypoglycemia), which are improved by eating. The diagnosis of an insulinoma is usually made biochemically with low blood glucose, elevated insulin, proinsulin, and C-peptide levels, and confirmed by localizing the tumour with medical imaging or angiography. The definitive treatment is surgery.
=== Chelation therapy === Chelation therapy is an antidote for poisoning by mercury, arsenic, and lead. Chelating agents convert these metal ions into a chemically and biochemically inert form that can be excreted. Chelation using sodium calcium edetate has been approved by the U.S. Food and Drug Administration (FDA) for serious cases of lead poisoning. It is not approved for treating "heavy metal toxicity". Although beneficial in cases of serious lead poisoning, use of disodium EDTA (edetate disodium) instead of calcium disodium EDTA has resulted in fatalities due to hypocalcemia. Disodium EDTA is not approved by the FDA for any use, and all FDA-approved chelation therapy products require a prescription.
=== Operation Edzell === An undercover policewoman from the Metropolitan Police Special Operations Group (SO10) contacted Stagg, posing as a friend of a woman with whom he used to be in contact via a lonely hearts' column. Over five months, she attempted to obtain information from him by feigning a romantic interest, meeting him, speaking to him on the telephone and exchanging letters containing sexual fantasies. During a meeting in Hyde Park, they spoke about the Nickell homicide; he later said that he had only played along with the topic because he wanted to pursue the romance. Profiler Paul Britton later said that he disagreed with use of the fantasy-filled letters and knew nothing of them until after they had been sent. The undercover officer won Stagg's confidence and drew out fantasies from him that psychologist Paul Britton interpreted as "violent", but he did not admit to the killing. Police released a taped conversation between the police officer and him, in which she claimed to enjoy hurting people, to which he mumbled, "Please explain, as I live a quiet life. If I have disappointed you, please don't dump me. Nothing like this has happened to me before". When she went on to say, "If only you had done the Wimbledon Common murder, if only you had killed her, it would be all right", he replied, "I'm terribly sorry, but I haven't". Stagg was nevertheless arrested and charged on the basis of claims that he had described aspects of the murder scene that only the killer would have known.
== Types == The mutated cells are mature T-lymphocytes and contain CD4+ receptors on the membrane surface. There are two variants of this mutated cell, Lutzner cells and Sézary cells. Sometimes these names are interchangeable, but it has been determined through histology that they are morphologically different.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.